Meeting
2014 Genitourinary Cancers Symposium
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.
Authors
Matthew R. Smith
Harvard Medical School and Massachusetts General Hospital, Boston, MA
Matthew R. Smith , Robert E. Coleman , Laurence Klotz , Kenneth B. Pittman , Piotr Milecki , Rachel Wei , Arun Balakumaran , Karim Fizazi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT00321620
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 35)
DOI
10.1200/jco.2014.32.4_suppl.35
Abstract #
35
Poster Bd #
B19
Abstract Disclosures
Similar Posters
Poster
2012 Genitourinary Cancers Symposium
Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
First Author: Michael E. Rader
Poster
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2011 ASCO Annual Meeting
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain.
First Author: N. D. Shore
Poster
2015 Genitourinary Cancers Symposium
Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA).
First Author: Matthew Raymond Smith